Sentences with phrase «how different cancers»

Dr Madhu Basetti, co-lead researcher also based at the Cancer Research UK Cambridge Institute, said: «Our study is the first to use this approach to compare how different cancers use and produce energy, and look for similarities.

Not exact matches

How can businesses offer employees discounted access to services, i.e., rather than pay for a set kind of insurance, can they offer a menu of different options for employees, such as pet insurance, a specific kind of medical insurance (like cancer insurance) or any other possibilities?

While it has shown promise for some types of tumors and become standard of care for others, researchers are just beginning to explore how different immunotherapy technologies can be applied to brain cancer.

Discover what AI solutions are being used currently in hospitals, clinics, and health networks, and how they're improving operations in vastly different corners of the industry, from increasing efficiency in EMRs and data - mining all the way to providing life - saving cancer diagnoses.

Cancer Research UK carries out world - class research to improve understanding of the disease and find out how to prevent, diagnose and treat different kinds of caCancer Research UK carries out world - class research to improve understanding of the disease and find out how to prevent, diagnose and treat different kinds of cancercancer..

A Case Western Reserve University School of Medicine researcher has compiled evidence from more than 100 publications to show how obesity increases risk of 13 different cancers in young adults.

Work still needs to be done to determine exactly how much gelsolin indicates a cancer that is chemo - resistant and would require different treatment options.

That trend is problematic considering that African - Americans — the most at - risk population for multiple myeloma — have different genetics that can affect how this type of cancer progresses and what kind of targeted therapies are most effective, said Zarko Manojlovic, lead author of the study.

Slusher teamed up with Johns Hopkins Kimmel Cancer Center immunologist Jonathan Powell, M.D., Ph.D., who has studied how cancer cells use different metabolic pathways to evade destruction by immune Cancer Center immunologist Jonathan Powell, M.D., Ph.D., who has studied how cancer cells use different metabolic pathways to evade destruction by immune cancer cells use different metabolic pathways to evade destruction by immune cells.

To understand how these multi-colored lesions originated they examined blood from these mice and found that tumor cells in circulation frequently occurred as clusters comprised of different colored cancer cells.

This work was carried out with funding from the Association for International Cancer Research (United Kingdom), the Lymphoma Research Foundation (USA) and the Instituto de Salud Carlos III (Spain), and illustrates how new genome sequencing technologies are revolutionizing the study of different types of cCancer Research (United Kingdom), the Lymphoma Research Foundation (USA) and the Instituto de Salud Carlos III (Spain), and illustrates how new genome sequencing technologies are revolutionizing the study of different types of cancercancer.

Then, they estimated enrichment factors by determining how frequently those known cancer - associated genes occurred among the top gene candidates identified by different analysis methods.

It's up to us to learn how different animals tackle the problem so we can adapt those strategies to prevent cancer in people,» says co-senior author Joshua Schiffman, M.D., pediatric oncologist at Huntsman Cancer Institute, University of Utah School of Medicine, and Primary Children's Hoscancer in people,» says co-senior author Joshua Schiffman, M.D., pediatric oncologist at Huntsman Cancer Institute, University of Utah School of Medicine, and Primary Children's HosCancer Institute, University of Utah School of Medicine, and Primary Children's Hospital.

«So perhaps in this age of cancer genomics showing how diverse and heterogenous human cancer is, we should be focusing on the common effects that different mutations lead to,» he says.

New Scientist spoke to breast cancer specialist Allison Kurian, of Stanford University in California who has developed a tool that enables women to determine how different treatment options can reduce their overall risk.

«If we could build a «family tree» of all cancer nodules in a patient, we could determine how different tumors are related to each other and reconstruct how the cancer evolved,» says Kamila Naxerova, PhD, of the Steele Laboratory for Tumor Biology at Massachusetts General Hospital (MGH), corresponding author of the report being published in PNAS Early Edition.

Chronically - ill cancer patients have different exercise limitations than their healthy counterparts and other concurrent diseases and high symptom burden add challenges in how best to study and implement physical activity programs in lung cancer patients.

The study used a well - known line of pancreatic cancer cells (AsPC - 1) in the laboratory and assessed how well this grew when treated with either the chemotherapy drug gemcitabine or different levels of commercially available chokeberry extract alone, and when treated with a combination of gemcitabine and chokeberry extract.

These cells have different factors on their surfaces which determines how «sticky» the cells are and whether they are responsible for mediating the cancer cells binding to the blood vessel walls.

Analyzing the poly - G profiles of primary and metastatic colon cancer samples from 22 patients revealed that how the primary and metastatic tumors related to each other was different for each patient.

Their recent study, which appears as the cover article in the May issue of Cancer Research, shows that mathematical models can be used to predict how different tumor cell populations interact with each other and respond to a changing environment.

Answering important clinical questions — such as whether genetic diversity is a risk factor for aggressive tumor development or how it relates to treatment resistance — requires analyzing samples from many patients with different types of cancer.

This finding provides an explanation for how the same cancer - causing mutation can give rise to different types of brain malignancies.

«The cancer stem cells actively regrow and respond to the induced damage or apoptosis (cell death) caused by chemotherapy in between the different cycles, similar to how normal tissue stem cells respond to wound - induced damages.»

To establish how different variants affect the risk of lung cancer, for instance, scientists now realize they can not look at the DNA and medical records of just 100 people.

Dr. David Gilley's laboratory at the Indiana University School of Medicine in Indianapolis and Dr. Connie Eaves» laboratory at the BC Cancer Agency's Terry Fox Laboratory in Vancouver, Canada, collaborated to determine how telomeres are regulated in different types of normal breast cells.

Gene expression profiling tests, such as Oncotype Dx, analyze the patterns of 21 different genes within cancer cells to help predict how likely it is that a women's cancer will recur within 10 years after initial treatment and how beneficial chemotherapy will be to her.

They're continuing to sequence prostate tumors to learn how frequently different mutations occur, as well as studying which of the rearranged genes are actually driving cancer.

We provide initial insights into two critical issues: what clinical value can be extracted from different commercial and academic cancer genomic platforms, and how to think about scaling access to that value,» noted the study's Principal Investigator, Robert Darnell, MD, PhD, Robert and Harriet Heilbrunn Professor and Senior Attending Physician at The Rockefeller University and Founding Director of the New York Genome Center.

A study led by scientists from Harvard Medical School reveals «hidden» variability in how tumor cells are affected by anticancer drugs, offering new insights on why patients with the same form of cancer can have different responses to a drug.

Christofk studies the genes and proteins behind the way cancer cells use sugars to live and grow, which is different from how normal cells do.

Blueprint will see where it stands after adding more patients with different cancer types to the Phase 1 study and focusing more on how long their responses last, rather than just whether they respond at all.

Recruiting diverse participants to these trials allows us to better understand how cancer and its treatments impact different communities and people differently.

Studying cancer with single - cell technology will allow us to unlock the interactions between different types of cells in tumors — and monitor how these interactions change over time, affecting patients» outcomes.

But no matter how many different ways they did their experiments, the Salk researchers found that TGF - β can interfere with cells» damage responses in premalignant or cancer cells.

Beverly Emerson studies how different genes are turned on and off through the course of a cancer — from the time cells become precancerous until the time they develop into a mature cancer and spread to new organs.

As part of their ongoing research, Ratain and O'Donnell are actively seeking out genetic biomarkers that shed light on how cancer patients will respond to different treatments.

And we can also use what we know about the genetics of the human cancer to make mutations in normal cells, and see how different mutations drive invasion.»

A better understanding of how the immune system works to fight cancer and a detailed characterisation of the different immune cells that infiltrate a particular patient's tumour, would enable more efficient treatments.

In this research study we are going to determine how safe and well tolerated the study drug INCB059872 is in subjects with different types of cancer.

The researchers also could not assess how many cancers developed from the site of the initial suspicious mammographic finding and how many were missed cancers from a different location, including the other breast.

We learn which specific genes are expressed in cancer cells and how a patient may respond to different therapies, so that we can select the most appropriate targeted treatment for the particular cancer.

It's up to us to learn how different animals tackle the problem so we can adapt those strategies to prevent cancer in people.

So how do you figure out what's different between cancers so you can develop new therapies in the face of those differences?

«Each child is different when it comes to predicting how they will respond to different cancer treatments,» Mody says.

«But breast cancer has lagged behind a bit and so we're trying to understand why it's different and how to make immunotherapy more effective for breast cancer patients.»

Dr. Gazit is focusing on how to develop targeted treatment of cancer cells using hematopoietic stem cells — stem cells used in cancer treatment because of their ability to divide and form new and different kinds of blood cells.

Ultimately the results will help the field of cancer research to learn how to combine and develop different therapies to achieve better clinical outcomes for leukaemia patients.

Stanton explains how these different types of fat contribute to excess weight, high blood pressure, heart disease, diabetes and various types of cancer.

Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study by Agnès Fournier, 1 Franco Berrino, 2 and Françoise Clavel - Chapelon1 * (9) http://bostonreview.net/BR35.3/angell.php Boston Review MAY / JUNE 2010 Big Pharma, Bad Medicine - How corporate dollars corrupt research and education by Marcia Angell